Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TPRG1 antisense RNA 1 (TPRG1-AS1)
- Target
- TPRG1-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Non-protein-coding RNA
01
Overview
TPRG1 antisense RNA 1 (TPRG1-AS1) is a human long non-coding RNA (lncRNA) that does not encode a protein, but instead functions as a regulator of gene expression, primarily via interactions with microRNAs and other gene regulatory molecules. TPRG1-AS1 is aberrantly upregulated in several malignancies, including cervical squamous cell carcinoma, where it promotes cancer cell proliferation, migration, and invasion by antagonizing the tumor-suppressive effects of miR-590-3p. It has also been shown to interact with the MYH9 protein and act as a prognostic biomarker in certain cancers. While this molecule is functionally important in disease context, it is not considered a direct therapeutic target such as a receptor, enzyme, or transporter, but instead represents a potential biomarker and mechanistic node for RNA-focused cancer research
- Other names
- TPRG1-AS1Tumor protein p63 regulated 1, antisense 1
02
Mechanism of action
Molecular sponge—binds to and inhibits the activity of tumor-suppressive microRNAs (such as miR-590-3p) impacting downstream gene regulation
03
Biological functions
Regulation of gene expression at the transcriptional and post-transcriptional levelNegative regulation of microRNA activity (acts as a “molecular sponge” for miR-590-3p)Modulation of cell proliferation, migration, and invasion in cancer cellsRegulation of oncogenic processes (not a receptor, enzyme, transporter, or transcription factor)
04
Disease associations
Cancer (especially cervical squamous cell carcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, bladder cancer, colon cancer)Potential involvement in atherosclerosis
05
Safety considerations
None directly known due to non-therapeutic target status; potential off-target concerns could arise if targeted by RNA-based therapeutics, but no clinically validated inhibitors or therapies targeting this lncRNA are known
06
Interacting drugs
Propofol
07
Biomarkers
Prognostic biomarker for several cancers, notably cervical squamous cell carcinoma (association with tumor size, lymph node metastasis, and survival independently of classic pathogenic factors)
Beyond the preview
Go deeper on TPRG1 antisense RNA 1 (TPRG1-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPRG1 antisense RNA 1 (TPRG1-AS1).